A change in direction?
Way back in the day when Medtronic owned the insulin pump space, we speculated that about the only way this would change was if they screwed it up. Which is exactly what happened. Today Tandem and Insulet dominate the insulin pump space with Medtronic now relegated to an afterthought. Tandem and Insulet have better products, better pipelines, and most importantly better management.
We’re beginning to wonder given with what’s going on at Abbott if the same thing is about to happen in the CGM market. Today Abbott and Dexcom own this market. As it stands now . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.